NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use

NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use

Introduction Intranasal (IN) naloxone is widely used to treat opioid overdoses. The advantage of nasal administration compared with injection lies in its suitability for administration by lay people as it is needless. Approved formulations of nasal naloxone with bioavailability of approximately 50%...

Full description

Bibliographic Details
Main Authors: Arne Kristian Skulberg, Ida Tylleskär, Anne-Cathrine Braarud, Jostein Dale, Fridtjof Heyerdahl, Sindre Mellesmo, Morten Valberg, Ola Dale
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/11/e041556.full

Internet

https://bmjopen.bmj.com/content/10/11/e041556.full

Similar Items